We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.95B
1-Year Est. Return 773.9%
This Fund
S&P 500
This Quarter Est. Return
+4.81%
1 Year Est. Return
+773.9%
3 Year Est. Return
+3,976.92%
5 Year Est. Return
+17,750.67%
10 Year Est. Return
+592,782.78%
AUM
$603M
AUM Growth
-$85.4M
Cap. Flow
-$61M
Cap. Flow %
-10.11%
Top 10 Hldgs %
45.31%
Holding
86
New
11
Increased
4
Reduced
19
Closed
15

Top Buys

Rank Stock Value
1
BLUE
bluebird bio
BLUE
+$25.6M
2
RXDX
Ignyta, Inc.
RXDX
+$12.2M
3
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$12M
4
OMER icon
Omeros
OMER
+$9.6M
5
GTHX
G1 Therapeutics, Inc. Common Stock
GTHX
+$8.4M

Top Sells

Rank Stock Value
1
TBPH icon
Theravance Biopharma
TBPH
+$18.3M
2
CRBP icon
Corbus Pharmaceuticals
CRBP
+$13.9M
3
FWP
Forward Pharma A/S American Depositary Shares
FWP
+$12.7M
4
ZYNE
Zynerba Pharmaceuticals, Inc
ZYNE
+$10.1M
5
CBPO
China Biologic Products Holdings, Inc.
CBPO
+$10M

Sector Composition

Rank Sector Weight
1 Healthcare 99.63%
2 Miscellaneous 0.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARDX icon
26
Ardelyx
ARDX
$875M
$7.26M 1.2%
1,422,738
-500,000
-26% -$4.24M
BOLD
27
DELISTED
Audentes Therapeutics, Inc
BOLD
$6.19M 1.03%
323,545
-101,115
-24% -$1.62M
PTGX icon
28
Protagonist Therapeutics
PTGX
$9.24B
$5.66M 0.94%
500,000
-183,600
-27% -$1.96M
SGYP
29
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$5.34M 0.89%
1,200,000
– –
CFRX
30
DELISTED
ContraFect Corporation
CFRX
$5.15M 0.85%
4,438
– –
DXCM icon
31
DexCom
DXCM
$33B
$5.12M 0.85%
280,000
– –
IVTY
32
DELISTED
Invuity, Inc
IVTY
$5.08M 0.84%
700,000
-56,470
-7% -$439K
JNCE
33
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$5.05M 0.84%
359,738
-75,238
-17% -$1.61M
DERM
34
DELISTED
Dermira, Inc.
DERM
$4.95M 0.82%
170,000
– –
FLGT icon
35
Fulgent Genetics
FLGT
$595M
$4.79M 0.79%
750,000
– –
SYRS
36
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$4.77M 0.79%
+29,630
New +$4.66M
AGEN
37
Agenus
AGEN
$326M
$4.69M 0.78%
61,140
– –
AGRX
38
DELISTED
Agile Therapeutics
AGRX
$4.69M 0.78%
625
– –
INDP icon
39
Indaptus Therapeutics
INDP
$428M
$4.62M 0.77%
362
– –
RIGL icon
40
Rigel Pharmaceuticals
RIGL
$831M
$4.2M 0.7%
153,975
-46,025
-23% -$1.26M
CRIS icon
41
Curis
CRIS
$2.72M
$3.78M 0.63%
1,000
– –
WVE icon
42
Wave Life Sciences
WVE
$887M
$3.76M 0.62%
202,079
-280,000
-58% -$6.03M
COLL icon
43
Collegium Pharmaceutical
COLL
$722M
$3.75M 0.62%
300,000
– –
CTMX icon
44
CytomX Therapeutics
CTMX
$604M
$3.56M 0.59%
230,000
– –
SGMO
45
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$3.52M 0.58%
400,000
-200,000
-33% -$1.28M
SRNE
46
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$3.38M 0.56%
1,690,800
– –
IMDZ
47
DELISTED
Immune Design Corp.
IMDZ
$3.29M 0.54%
337,000
– –
LPCN icon
48
Lipocine
LPCN
$17.8M
$2.98M 0.49%
43,617
– –
AAAP
49
DELISTED
Advanced Accelerator Applications S.A.
AAAP
$2.93M 0.49%
75,000
– –
TRIL
50
DELISTED
Trillium Therapeutics Inc.
TRIL
$2.64M 0.44%
+600,000
New +$3.32M
1
2
3 4

Similar funds

AHC
Adell Harriman & Carpenter Houston, Texas $1.95B AUM 52.72% 1-Year Est. Return
FFS
Founders Financial Securities Towson, Maryland $1.95B AUM 22.17% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.95B AUM 49.89% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.95B AUM 25.88% 1-Year Est. Return
BFPW
BOK Financial Private Wealth Denver, Colorado $1.95B AUM 20.52% 1-Year Est. Return
MSA
MUFG Securities Americas New York $1.95B AUM 42.71% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return
GF
Greenhouse Funds Baltimore, Maryland $1.96B AUM 36.47% 1-Year Est. Return

Cormorant Asset Management's Q2 2017 Portfolio in Review

As of Q2 2017, Cormorant Asset Management held 86 positions worth $603M, down 12% from $689M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Cormorant Asset Management withdrew a net $61M in Q2 2017, closing 15 positions and reducing 19 holdings. Its most notable exit was Corbus Pharmaceuticals, an estimated $13.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, Cormorant Asset Management opened a new position in bluebird bio worth $28.9M.

  • Cormorant Asset Management's largest Q2 2017 buy was bluebird bio: 21,230 shares worth $28.9M.
  • Cormorant Asset Management added most to Portola Pharmaceuticals, Inc. in Q2 2017, an estimated $12M increase.
  • Cormorant Asset Management's biggest Q2 2017 reduction was Theravance Biopharma, cutting an estimated $18.3M.
  • Cormorant Asset Management fully exited Corbus Pharmaceuticals in Q2 2017, selling an estimated $13.9M.
  • Cormorant Asset Management's ten largest holdings make up 45% of its $603M portfolio in Q2 2017.
  • Cormorant Asset Management opened 11 new positions and closed 15 in Q2 2017.
  • Cormorant Asset Management's portfolio value fell 12% quarter-over-quarter to $603M.

Based on Cormorant Asset Management's 13F filing for Q2 2017, filed 14 Aug 2017.